Inflammatory Bowel Disease:'New genes, rare variants &amp; moving towards clinical practice' by Visschedijk, Marijn
  
 University of Groningen
Inflammatory Bowel Disease
Visschedijk, Marijn
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2018
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Visschedijk, M. (2018). Inflammatory Bowel Disease: 'New genes, rare variants & moving towards clinical
practice'. [Groningen]: Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 13-11-2019
521405-L-sub01-bw-Visschedijk
Processed on: 23-7-2018 PDF page: 113
Lieke M Spekhorst*, Marijn C Visschedijk*, Rudi Alberts, Eleonora A Festen, Egbert-Jan van 
der Wouden, Gerard Dijkstra, Rinse K Weersma; Dutch Initiative on Crohn and Colitis (ICC)
World J Gastroenterol. 2014 Nov 7;20(41):15374-81.
*These authors contributed equally
Performance of the Montreal 








Aim: To validate the Montreal classification system for Crohn’s disease (CD) and 
ulcerative colitis (UC) within the Netherlands.
Methods: A selection of 20 de-identified medical records with an appropriate 
representation of the inflammatory bowel disease (IBD) sub phenotypes were scored 
by 30 observers with different professions (gastroenterologist specialist in IBD, 
gastroenterologist in training and IBD-nurses) and experience level with IBD patient care. 
Patients were classified according to the Montreal classification. In addition, participants 
were asked to score extra-intestinal manifestations (EIM) and disease severity in CD 
based on their clinical judgment. The inter-observer agreement was calculated by 
percentages of correct answers (answers identical to the “expert evaluation”) and Fleiss-
kappa (k). Kappa cut-offs: < 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent.
Results: The inter-observer agreement was excellent for diagnosis (k = 0.96), perianal 
disease (k = 0.92) and disease location in CD (k = 0.82) and good for age of onset (k = 
0.67), upper gastrointestinal disease (k = 0.62), disease behaviour in CD (k = 0.79) and 
disease extent in UC (k = 0.65). Disease severity in UC was scored poor (k = 0.23). The 
additional items resulted in a good inter-observer agreement for EIM (k = 0.68) and 
a moderate agreement for disease severity in CD (k = 0.44). Percentages of correct 
answers over all Montreal items give a good reflection of the inter-observer agreement 
(> 80%), except for disease severity (48%-74%). IBD-nurses were significantly worse in 
scoring upper gastrointestinal disease in CD compared to gastroenterologists (P = 0.008) 
and gastroenterologists in training (P = 0.040). Observers with less than 10 years of 
experience were significantly better at scoring UC severity than observers with 10-20 
years (P = 0.003) and more than 20 years (P = 0.003) of experience with IBD patient 
care. Observers with 10-20 years of experience with IBD patient care were significantly 
better at scoring upper gastrointestinal disease in CD than observers with less than 10 
years (P = 0.007) and more than 20 years (P = 0.007) of experience with IBD patient care. 
Conclusion: We found a good to excellent inter-observer agreement for all Montreal 
items except for disease severity in UC (poor).
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INTRODUCTION
Inflammatory bowel diseases (IBD) are common, chronic relapsing gastrointestinal 
inflammatory disorders consisting of mainly two diseases: Crohn’s disease (CD) and 
ulcerative colitis (UC). IBD affects approximately 1 in 1000 individuals in Western 
Europe1,2. 
In CD inflammation is transmural and can occur throughout the entire gastrointestinal 
tract, in UC the inflammation is limited to the mucosal layer of the colon3,4. In addition 
to intestinal inflammation, up to 25% of the patients have extra-intestinal symptoms 
like uveitis, arthritis and erythema nodosum. Management of IBD with drug therapy 
consists of mesalazine, corticosteroids, and immunosuppressants like azathioprine and 
anti-tumor necrosis factor (TNF) antibody therapies. Most of these treatments have 
significant side effects, are expensive and often ineffective. Half of the patients (25%-30% 
in UC, 70%-75% in CD) require surgical intestinal resections because of refractory disease, 
fibrostenotic disease, abscesses, fistulae or the development of colorectal cancer5–9. 
The pathogenesis of IBD is still not fully understood. The current hypothesis is that 
it arises from an inappropriate activation of the mucosal immune system in response 
to commensal bacteria in a genetically susceptible host10,11. Several biological pathways 
that play a role in this inappropriate inflammation have been identified through 
genetic studies. Recently, the International IBD Genetics Consortium has identified 
163 independent genetic susceptibility loci12–15. However, the translation of biological 
knowledge on the pathogenesis of IBD towards the clinic is complicated by the great 
variety in the clinical presentation of IBD. For both clinical and genetic research it is 
of great importance that phenotypes of patients are described in a consistent manner. 
In 2000 the Vienna classification16 was introduced, which was the first attempt to 
classify different clinical phenotypes of CD The Vienna classification was followed by 
the Montreal classification in 200817. The Montreal classification describes the extent 
and behaviour of CD in more detail and includes a classification system for UC (Table 
1)17. Although the Montreal classification is widely used in both research and clinical 
practice, there is very limited data available on its reliability. Only two studies assessed 
the inter-observer reliability and validity of the Montreal classification, an Australian-
New Zealand study and a study of the National Institutes of Diabetes and Digestive 
and Kidney Diseases IBD Genetics Consortium. Both studies had a small number of 
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observers. The Australian-New Zealand study assessed only reliability of the Montreal 
classification in CD. In both studies the inter-observer agreement was good for disease 
location, but only moderate/fair for upper gastrointestinal involvement18,19. 
The aim of this study is to validate the Montreal phenotype classification for both CD 
and UC in the Netherlands. Secondly, we will assess the influence of one’s profession 
(gastroenterologist, gastroenterologist in training, IBD-nurse) and level of experience (< 
10 years, 10-20 years, > 20 years) on the reliability of the Montreal classification scoring. 
Table 1 Montreal classification of Crohn’s disease, ulcerative colitis, non-classified chronic coli-




Non-classified chronic colitis (IBD-U)
Indeterminate colitis (IBD-I)
Age of onset (A) (20 case-vignettes)
A1: 16 years or younger
A2: 17-40 years
A3: over 40 years
CD (10 case-vignettes) UC, IBD-U, IBD-I (10 case-vignettes)





P:   Perianal disease
E1: Proctitis
E2: Left-sided UC; proximal extent of 
inflammation is distal to the rectosigmoid
E3: Extensive UC; involvement extends 
proximal to the splenic flexure. 




S0: Remission, no symptoms
S1: Mild, ≤4x/day stools, no systemic signs of 
toxicity, normal ESR
S2: Moderate, >4x/day stools, minimal 
systemic signs of toxicity 
S3: Severe, ≥6x/day stools, pulse >90 beats/
min, temperature >37,5, Hemoglobin <6,5 
mmol/L, ESR >30mm  
EIM: Extra-intestinal manifestations; ESR: Erythrocyte sedimentation rate.
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MATERIAL AND METHODS
Cases and observers
Twenty patient records were selected from the specialized IBD unit of the Department 
of Gastroenterology and Hepatology of the University Medical Center Groningen, the 
Netherlands (10 case vignettes) and the IBD unit of the Gastroenterology and Hepatology 
department of the non-university medical center Isala Clincs, Zwolle, the Netherlands 
(10 case vignettes). The case vignettes consisted of clinical-, endoscopy-, pathology- 
and operation reports. All case vignettes were anonymized and the selection gave an 
appropriate representation of the IBD sub phenotypes (Figure 1).
Figure 1
Figure 1 Distribution of the different categories of the Montreal classification for all 20 case 
vignettes that were scored by 30 observers. CD: Crohn’s disease; IBD: Inflammatory bowel 
disease; UC: Ulcerative colitis; EIM: Extra-intestinal manifestations.
6
521405-L-sub01-bw-Visschedijk
Processed on: 23-7-2018 PDF page: 118
118
Chapter 6
The expert panel consisted of two gastroenterologists experienced in IBD care (Dijkstra 
G, Weersma RK), and one gastroenterologist/PhD in training (Visschedijk MC). The 
expert panel first assessed the 20 case vignettes separately, discussed their findings and 
developed an “expert evaluation” for all Montreal items in the 20 case vignettes. This 
“expert evaluation” was considered as the correct answer. Two additional items were 
added. Firstly, CD severity was added, because the Montreal classification only allows 
scoring severity of UC. The Montreal classification does not include any parameters 
to score severity of CD, therefore observers were asked to give an impression of CD 
severity (mild, moderate, severe) based on their own clinical experience and judgment. 
Secondly, observers were asked to score whether any extra-intestinal manifestations 
(EIM) were present.
The 20 case vignettes were sent to 49 observers with different experience levels and 
professions: gastroenterologists specialized in IBD, gastroenterologists in training 
and IBD-nurses with a day-to-day experience with IBD patients, all from university 
and non-university medical centers. The observers received the selected 20 case 
vignettes, instructions by e-mail and a hyperlink to fill out the online survey (https://
www.enquetesmaken.com/), in which the Montreal classification and the two additional 
items, EIM and CD severity, had to be scored. 
The online survey contained the following main items: diagnosis, age of onset and EIM. 
For the CD case vignettes the observers had to fill in disease location, disease behavior 
and disease severity. For the UC case vignettes the observers had to score disease extent 
and disease severity (Table 1). The diagnosis of CD and UC is standardized and uniformly 
accepted. However, in 10%-20% of the patients it is difficult to differentiate between CD 
and UC. These patients are classified as having non-classified chronic colitis (IBD-U). If 
the pathologist can’t differentiate between CD and UC after a colectomy, the patient is 
classified as having indeterminate colitis (IBD-I)20–22. Case vignettes with the diagnosis 
IBD-U or IBD-I are scored as UC, according to the Montreal classification.
Statistical analysis
Statistical analysis was performed using R statistical software. Firstly the inter-observer 
agreement was calculated using percentages of correct answers. An answer was scored 
correct if the answer of the observer was identical to the “expert evaluation”, percentages 
of correct answers were calculated for all items. 
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Secondly Fleiss-kappa (k) was calculated, which is the standard method to calculate the 
inter-observer agreement for multiple observers. An observer can only be included in 
the statistical analysis on the condition that one Montreal item is scored by the observer 
in all case vignettes. In case of one missing value in one case vignette the observer was 
excluded from the statistical analysis for this item. The Fleiss-kappa cut-offs were set as 
follows: < 0.4 poor agreement; 0.41-0.60 moderate agreement; 0.61-0.8 good agreement; 
> 0.8 excellent agreement. 
Subgroup analyses for the inter-observer agreement between profession 
(gastroenterologist, gastroenterologist in training, IBD-nurse) and level of experience 
(< 10 years; 10-20 years; > 20 years) were performed by percentages of correct answers. 




The online survey was available for six weeks, in which the 49 observers received several 
reminders. Eventually 30 of the 49 observers completed the survey, a response rate of 
61%. Details of the observers are depicted in Table 2. Fifty-four percent of the responders 
were gastroenterologist and 67% of the observers had less than 10 years experience with 
IBD patient care. 
Table 2 Characteristics of 30 observers n (%)
< 10 yr of 
experience with 
IBD patients
10-20 yr of 
experience with 
IBD patients











Gastroenterologist 7 (23%) 5 (17%) 4 (13%) 5 (17%) 11 (37%) 16 (54%)
Gastroenterologist 
in training
10 (33%) 3 (10%) 7 (23%) 10 (33%)
IBD-nurse 3 (10%) 1 (3%) 1 (3%) 3 (10%) 4 (13%)
Total 20 (67%) 6 (20%) 4 (13%) 100%
IBD: Inflammatory bowel disease.
6
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Average percentage of correctly answered questions for all Montreal and additional 
items (CD severity and EIM) by different professions was 85%. Age of onset, disease 
location, perianal disease and disease behaviour in CD had more than 90% correct score 
over all professions. Disease severity in UC was the worst scored item overall with less 
than 55% correctly scored by all three professions (Table 3). 
Table 3 Percentages of correct answers according to the “expert evaluation” for overall and 









Age of onset 94.0% 94.2% 96.8% 86.0%
Diagnosis 96.9% 96.0% 96.0% 98.8%
CD disease Localization 94.0% 90.6% 93.8% 97.5%
CD upper gastrointestinal 91.3% 95.6% 94.0% 84.2%
CD perianal disease 98.0% 99.4% 98.0% 96.7%
CD Disease behaviour 92.4% 92.4% 94.8% 90.0%
CD severity
(mild, moderate, severe)
73.9% 68.7% 72.9% 80.0%
UC disease extent 84.0% 89.3% 85.2% 77.5%
UC disease severity colitis 50.7% 53.9% 50.7% 47.5%
EIM 82.1% 82.1% 85.8% 78.5%
EIM: Extra-intestinal manifestations; CD: Crohn’s disease; UC: Ulcerative colitis.
When observers were grouped according to their profession, the additional item severity 
of the disease (CD), was scored worst by the gastroenterologists (69%) and best by the 
IBD nurses (80%). IBD-nurses had an excellent correct score on diagnosis (99%) as well 
as the gastroenterologists (96%) and gastroenterologists in training (96%). According to 
the fisher exact test, no significant differences were found between the three professions 
except for scoring of upper gastrointestinal disease in CD, in which IBD-nurses scored 
significantly worse than gastroenterologists (P = 0.008) and gastroenterologists in 
training (P = 0.040). 
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After calculation of the percentages of correct answers for the observers based on their 
level of experience, all items of the Montreal classification and the EIM scored above 
80%, except for disease severity in UC (48%). The additional item, CD severity, was scored 
correctly in 70% of cases. Observers with less than 10 years of experience performed 
best at scoring disease severity (Table 4) and were significantly better at scoring UC 
severity than observers with 10-20 years (P = 0.003) and more than 20 years (P = 0.003) 
of experience with IBD patient care. Observers with 10-20 years of experience with 
IBD patient care were significantly better at scoring upper gastrointestinal disease in CD 
than observers with less than 10 years (P = 0.007) and more than 20 years (P = 0.007) of 
experience with IBD patient care. 
For scoring disease severity in UC, the Montreal requires to score the maximum disease 
severity ever experienced. Therefore, scoring S0 (meaning clinical remission) would be 
impossible. We therefore removed observers that scored an S0, and disease severity in 
UC was calculated again for gastroenterologists and gastroenterologists in training. The 
percentages of correct answers were 69% and 71%. IBD-nurses were not considered in 
this analysis because all scored an S0 once or more. Removing S0 for disease severity in 
UC led to a correct score of 77%, 56% and 56% for observers with less than 10 years, 10-20 
years and more than 20 years of experience with IBD patient care. 
Inter-observer agreement
The inter-observer agreement was excellent for diagnosis (k = 0.96), CD location (k = 
0.82) and perianal disease (k = 0.91). Age of onset (k = 0.67) and upper gastrointestinal 
disease (k = 0.62) were scored with a good inter-observer agreement. Disease severity 
was scored poorly (k = 0.23) for UC. The additional clinical item, CD severity, was scored 
with moderate concordance (k = 0.44). In total there were 19 EIMs in 12 case vignettes. 
The inter-observer agreement for occurrence of EIM, was good (k = 0.68) (Table 5). 
By removing all the observers that stated an S0 once or more, only 7 observers remained 
which led to a kappa of 0.57, resulting in moderate inter-observer agreement for severity 
in UC. Kappa was also calculated again for disease extent and disease severity in UC, but 
now for 30 observers with all the missing values being replaced by the correct answer as 
established by the “expert evaluation”. No significant differences in the inter-observer 
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Table 5 Inter-rater agreement kappa for all items of all categories of Montreal classification
Item Montreal classification Overall kappa
Age of onset 0.67 (n = 28)
Diagnosis 0.96 (n = 28)
CD disease localization 0.82 (n = 28)
CD upper gastrointestinal 0.62 (n = 28)
CD perianal disease 0.91 (n = 28)
CD disease behaviour 0.79 (n = 26)
CD severity (mild, moderate, severe) 0.44 (n = 24)
UC disease extent 0.65 (n = 21)
UC disease severity colitis 0.23 (n = 20)
EIM 0.68 (n = 28)
Observers were only included if they scored at least one item in all case-vignettes. EIM: Extra-intestinal mani-
festations; CD: Crohn’s disease; UC: Ulcerative colitis.
DISCUSSION
The aim of this study was to assess the validity of accurate phenotyping using the 
Montreal IBD classification system with 2 additional items (CD severity and EIM) for 
both CD and UC within the Netherlands. 
According to our study, the Montreal is a reliable classification system for phenotypes 
in IBD, except for disease severity in UC. The assessment of disease severity for UC as 
described in the Montreal classification system is difficult in the case of retrospective 
chart reviews. Since severity in CD is not a classification item in the Montreal, we asked 
the observers to score CD severity based on their personal interpretation of the case 
vignettes. This resulted in a low consistency between observers, but this item was scored 
with higher concordance (with fewer instructions) than disease severity in UC. 
Until now only limited data on the reliability and reproducibility of the Montreal 
classification is available. An Australian-New Zealand and United States study18,19 found 
a good inter-observer agreement for CD, however the Australian-New Zealand study 
did not include the scoring of UC and neither study included an assessment of disease 
severity for both UC and CD. In our study the inter-observer agreement for diagnosis 
was excellent (k = 0.96), which was comparable to the Australian-New Zealand study (k = 
0.82). The inter-observer agreement for age of onset was only “good” in our cohort (k = 
0.67) as compared to excellent in the Australian-New Zealand (k = 0.84) and the US study 
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(k = 0.98). The observers in our cohort were better at scoring disease localization in 
CD, upper gastrointestinal involvement, perianal disease and disease behaviour in CD. 
Disease extent in UC was similarly scored in our cohort (k = 0.65) as in the Australian-
New Zealand study (k = 0.67)18,19. 
Classifying disease severity in patients’ records (“real life”) is still a problem because of 
missing or unclear descriptions. Clinicians should strive to be complete and accurate 
in their medical reporting. A clearer definition of disease severity is needed because 
apparently there is no consensus between clinicians about mild, moderate or severe 
disease in (real life) patients. For disease severity there are several classification systems 
e.g., CD activity index23 and the UC activity index24 that assess disease severity by clinical 
symptoms, however these symptoms are present at a specific time point and cannot be 
assessed in a retrospective manner. The CD digestive damage score (Lemann score) is 
a measurement for cumulative structural bowel damage, assessed by scoring disease 
severity for damage location, severity, extent, progression and reversibility, diagnosed 
Table 4 Percentages of correct answers compared to the “expert evaluation” overall and divid-
ed for different years of experience with inflammatory bowel disease patients
Overall correct 
answers
< 10 yr of 
experience
10-20 yr of 
experience
> 20 yr of 
experience
Age of onset 92.3% 95.2% 93.0% 88.6%
Diagnosis 96.2% 97.0% 93.3% 98.3%
CD disease localization 90.6% 94.2% 90.0% 87.5%
CD upper gastrointestinal 94.8% 91.8% 100.0% 92.5%
CD perianal disease 98.9% 98.5% 98.3% 100.0%
CD disease behaviour 93.0% 92.3% 96.7% 90.0%
CD severity
(mild, moderate, severe)
69.9% 73.1% 70.0% 66.7%
UC disease extent 86.6% 86.2% 85.3% 88.3%
UC disease severity colitis 48.0% 56.2% 37.7% 50.0%
EIM 83.4% 82.7% 81.6% 86.0%
EIM: Extra-intestinal manifestations; CD: Crohn’s disease; UC: Ulcerative colitis.
6
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by image modalities and the history of surgical resections. Ultimately a prediction 
model gives a reflection of progressive and destructive disease course25. The Lemann 
score might be a good instrument for classifying disease severity. 
Since IBD is a chronic disease with unpredictable disease behaviour, it is very important 
that clinicians can identify those individuals with a severe disease course, risk of 
side effects to therapy or those who would benefit from lifestyle or environmental 
changes. It is expected that molecular and/or pharmaco-genetic markers will play an 
increasing role in predicting disease course or response to medication in the future26. 
A good opportunity to predict individual disease behaviour is by linking their uniform 
phenotypic characteristics with our knowledge of the molecular basis of the disease. In 
IBD research an increasing number of biobanks are being set up worldwide allowing 
for linking molecular data to phenotypic data. To ensure high-quality data, validation 
of the Montreal classification is mandatory for these kinds of multicenter prospective 
data collections. 
This Dutch validation study has a larger observer group than the previously mentioned 
studies. It is the first to include UC and CD disease severity, and to differentiate between 
professions. We found a good inter-observer agreement for diagnosis, localization, 
disease behaviour, disease extent and the occurrence of EIM. The reliability for 
assessment of disease severity for UC was poor, and moderate for the additional CD 
severity item. Optimal reporting of uniform phenotypes of patient cohorts is of utmost 
importance, especially in genetic and clinical research. Uniform phenotyping will 
ultimately allow for integration of clinical phenotypes with high-throughput–omics 
data (integration of genetic, expression or metagenomic data), which will increase 
our understanding of IBD pathogenesis, and allow for better patient stratification and 
classification.
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